MedTrace Logo

Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma

NCT01051583 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-01-18

No results posted yet for this study

Summary

Assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the treatment of Neovascular Glaucoma.

Conditions

  • Neovascular Glaucoma

Interventions

PROCEDURE

Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin

The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).

Sponsors & Collaborators

  • AL-Nour Eye Hospital

    collaborator OTHER

  • Kasr El Aini Hospital

    collaborator OTHER

  • Cairo University

    lead OTHER

Principal Investigators

  • Mostafa A EL-Helw, M.D. · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01051583 on ClinicalTrials.gov